Stock Track | Krystal Biotech (KRYS) Soars 5.28% as Chardan Capital Raises Price Target

Stock Track11-04

Shares of Krystal Biotech Inc. (KRYS) are soaring 5.28% in Tuesday's trading session, following a positive analyst update from Chardan Capital. The biotechnology company's stock is gaining momentum as investors react to the reaffirmed bullish stance and increased price target from a key analyst.

Chardan Capital has maintained its "Buy" rating on Krystal Biotech while raising its price target from $216 to $220. This upward revision in the price target suggests increased confidence in the company's future prospects. The new target represents a significant upside potential from the stock's current trading levels, likely contributing to the surge in investor interest.

The positive analyst sentiment aligns with the broader market view on Krystal Biotech. According to analysts polled by FactSet, the company has an average rating of "Buy" and a mean price target of $222.46. This consensus outlook indicates that Wall Street remains optimistic about Krystal Biotech's growth potential and market position in the biotechnology sector. As investors digest this information, the stock's upward movement reflects growing confidence in the company's future performance and potential returns.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170276918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 23:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170276918","market":"nz","top_or_hot":-1,"title":"Stock Track | Krystal Biotech (KRYS) Soars 5.28% as Chardan Capital Raises Price Target","media":"Stock Track","content":"<p>Shares of Krystal Biotech Inc. (KRYS) are soaring 5.28% in Tuesday's trading session, following a positive analyst update from Chardan Capital. The biotechnology company's stock is gaining momentum as investors react to the reaffirmed bullish stance and increased price target from a key analyst.</p>\n\n<p>Chardan Capital has maintained its \"Buy\" rating on Krystal Biotech while raising its price target from $216 to $220. This upward revision in the price target suggests increased confidence in the company's future prospects. The new target represents a significant upside potential from the stock's current trading levels, likely contributing to the surge in investor interest.</p>\n\n<p>The positive analyst sentiment aligns with the broader market view on Krystal Biotech. According to analysts polled by FactSet, the company has an average rating of \"Buy\" and a mean price target of $222.46. This consensus outlook indicates that Wall Street remains optimistic about Krystal Biotech's growth potential and market position in the biotechnology sector. As investors digest this information, the stock's upward movement reflects growing confidence in the company's future performance and potential returns.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech (KRYS) Soars 5.28% as Chardan Capital Raises Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech (KRYS) Soars 5.28% as Chardan Capital Raises Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 23:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Krystal Biotech Inc. (KRYS) are soaring 5.28% in Tuesday's trading session, following a positive analyst update from Chardan Capital. The biotechnology company's stock is gaining momentum as investors react to the reaffirmed bullish stance and increased price target from a key analyst.</p>\n\n<p>Chardan Capital has maintained its \"Buy\" rating on Krystal Biotech while raising its price target from $216 to $220. This upward revision in the price target suggests increased confidence in the company's future prospects. The new target represents a significant upside potential from the stock's current trading levels, likely contributing to the surge in investor interest.</p>\n\n<p>The positive analyst sentiment aligns with the broader market view on Krystal Biotech. According to analysts polled by FactSet, the company has an average rating of \"Buy\" and a mean price target of $222.46. This consensus outlook indicates that Wall Street remains optimistic about Krystal Biotech's growth potential and market position in the biotechnology sector. As investors digest this information, the stock's upward movement reflects growing confidence in the company's future performance and potential returns.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1170276918","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170276918","pubTimestamp":1762270587,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Krystal Biotech Inc. (KRYS) are soaring 5.28% in Tuesday's trading session, following a positive analyst update from Chardan Capital. The biotechnology company's stock is gaining momentum...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"股票追踪|Chardan Capital上调目标价，Krystal Biotech(KRYS)飙升5.28%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Shares of Krystal Biotech Inc. (KRYS) are soaring 5.28% in Tuesday's trading session, following a positive analyst update from Chardan Capital. The biotechnology company's stock is gaining momentum as investors react to the reaffirmed bullish stance and increased price target from a key analyst.\nChardan Capital has maintained its \"Buy\" rating on Krystal Biotech while raising its price target from $216 to $220. This upward revision in the price target suggests increased confidence in the company's future prospects. The new target represents a significant upside potential from the stock's current trading levels, likely contributing to the surge in investor interest.\nThe positive analyst sentiment aligns with the broader market view on Krystal Biotech. According to analysts polled by FactSet, the company has an average rating of \"Buy\" and a mean price target of $222.46. This consensus outlook indicates that Wall Street remains optimistic about Krystal Biotech's growth potential and market position in the biotechnology sector. As investors digest this information, the stock's upward movement reflects growing confidence in the company's future performance and potential returns.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170276918","isCrawlerRequest":true}